Targeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic Virotherapy

While clinical responses to palbociclib have been promising, metastatic breast cancer remains incurable due to the development of resistance. We generated estrogen receptor-positive (ER+) and ER-negative (ER−) cell line models and determined their permissiveness and cellular responses to an oncolyti...

Descripción completa

Detalles Bibliográficos
Autores principales: Lypova, Nadiia, Lanceta, Lilibeth, Gipson, Alana, Vega, Stephanie, Garza-Morales, Rodolfo, McMasters, Kelly M., Chesney, Jason, Gomez-Gutierrez, Jorge G., Imbert-Fernandez, Yoannis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563125/
https://www.ncbi.nlm.nih.gov/pubmed/31100952
http://dx.doi.org/10.3390/cancers11050684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563125/
https://www.ncbi.nlm.nih.gov/pubmed/31100952
http://dx.doi.org/10.3390/cancers11050684

Ejemplares similares